Biogen (BIIB) Bullish View Reiterated at Jefferies Following Sensitivity Analysis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results
October 21, 2015 1:42 PM EDTLeerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported a 3Q beat on all top and bottom line levels. 3Q sales of 2.78 bn. vs. consensus estimates of $2.6B, 3Q non-GAAP EPS of 4.48 vs.... More
Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat
October 21, 2015 1:36 PM EDTCowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported strong Q3 non-GAAP EPS of $4.48 vs. consensus of $3.84E, on revenue of $2.8B.
Analyst Eric Schmidt commented, "BIIB reported Q3 revenue and earnings well above... More
